1. Home
  2. XERS vs ALF Comparison

XERS vs ALF Comparison

Compare XERS & ALF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XERS
  • ALF
  • Stock Information
  • Founded
  • XERS 2005
  • ALF 2024
  • Country
  • XERS United States
  • ALF United States
  • Employees
  • XERS N/A
  • ALF N/A
  • Industry
  • XERS Biotechnology: Pharmaceutical Preparations
  • ALF
  • Sector
  • XERS Health Care
  • ALF
  • Exchange
  • XERS Nasdaq
  • ALF NYSE
  • Market Cap
  • XERS 444.0M
  • ALF 360.5M
  • IPO Year
  • XERS 2018
  • ALF 2024
  • Fundamental
  • Price
  • XERS $3.09
  • ALF $10.04
  • Analyst Decision
  • XERS Buy
  • ALF
  • Analyst Count
  • XERS 3
  • ALF 0
  • Target Price
  • XERS $4.87
  • ALF N/A
  • AVG Volume (30 Days)
  • XERS 1.9M
  • ALF 38.9K
  • Earning Date
  • XERS 11-08-2024
  • ALF 01-01-0001
  • Dividend Yield
  • XERS N/A
  • ALF N/A
  • EPS Growth
  • XERS N/A
  • ALF N/A
  • EPS
  • XERS N/A
  • ALF N/A
  • Revenue
  • XERS $187,361,000.00
  • ALF N/A
  • Revenue This Year
  • XERS $20.35
  • ALF N/A
  • Revenue Next Year
  • XERS $16.14
  • ALF N/A
  • P/E Ratio
  • XERS N/A
  • ALF N/A
  • Revenue Growth
  • XERS 22.72
  • ALF N/A
  • 52 Week Low
  • XERS $1.69
  • ALF $9.96
  • 52 Week High
  • XERS $3.64
  • ALF $10.25
  • Technical
  • Relative Strength Index (RSI)
  • XERS 49.74
  • ALF N/A
  • Support Level
  • XERS $2.82
  • ALF N/A
  • Resistance Level
  • XERS $3.12
  • ALF N/A
  • Average True Range (ATR)
  • XERS 0.18
  • ALF 0.00
  • MACD
  • XERS -0.03
  • ALF 0.00
  • Stochastic Oscillator
  • XERS 32.93
  • ALF 0.00

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

About ALF CENTURION ACQUISITION CORP

Centurion Acquisition Corp is a blank check company.

Share on Social Networks: